Rationale: Choline (CH) positron emission tomography (PET)/computed tomography (CT) with fluorine 18 ( 18 F) CH is increasingly used not only to evaluate patients with biochemically recurrent prostate cancer but also to assess metastatic lesions that are difficult or impossible to identify using more conventional modalities. Our experience with CH PET/CT has shown that it can also be used for many other malignancies.
Introduction
Neuroendocrine tumors (NETs) represent a heterogeneous group of relatively rare neoplasms arising from cells of the endocrine system. [1] The incidence of these tumors is low (5.25/100,000/ year) but has increased significantly in recent years and prevalence is high (35/100,000/year) given of the long survival of these patients. [2] The medical approach to metastatic disease takes into account the anatomical origin, degree of differentiation, and endocrine function of the tumor, and includes numerous therapeutic options. NETs can be classified as functioning or nonfunctioning according to the presence or not of peptide or hormone secretion. In about 20% to 50% of cases, the primary tumor is of unknown origin, accounting for 2% to 4% of all cancers of unknown primary origin. [3] [4] [5] Tumor grade is determined on the basis of Ki67 proliferation index within the neoplastic cell population; low and medium grade lesions are classified as NETs, whereas high grade lesions are considered to be more aggressive and are classified as neuroendocrine carcinomas. [6] These neoplasms are characterized by an overexpression of somatostatin receptors.
68 Gallium ( 68 Ga)-DOTATOC positron emission tomography (PET)/computed tomography (CT) plays a crucial part in the diagnostic and therapeutic management strategies of these tumors. [7] [8] [9] F-fluorodeoxyglucose (FDG) is the most widely used glucose analog for PET imaging studies and is particularly sensitive for tumors exhibiting rapid and aggressive growth. [10] FDG uptake is closely linked to tumor vascularization and hydrocarbon metabolism and, therefore, to its replicating power. [11] Although radiolabeled choline (CH) PET/CT is widely accepted as a useful tool in prostate cancer staging, several human tumor-derived cell lines of different cancer histologies including breast, colon, prostate, lung, brain, and liver have shown an increased CH metabolism. [12, 13] Some authors have also indicated the potential usefulness of 11 C-and 18 fluoro ( 18 F)-labeled CH PET/CT in bronchial NETs. No data are available on NETs of different origin. [14, 15] We present the case of a 71-year-old patient with osteoblastic bone metastases positive to 18 F-CH PET/CT from a metastatic NET of unknown origin. A comparison was also performed between 18 F-CH PET/CT findings and 68 Ga PET/CT and 18 FDG PET/CT results. We also performed a brief review of the literature, focusing on solid tumors other than from prostate cancer detected by 18 F-CH PET/CT. Institutional review board approval and informed consent were waived as this was a retrospective case report with no identifying patient information presented.
Case presentation
Ethics approval was not necessary for this work due to its design (Case Report). Written informed consent was obtained from our patient for the submission of this manuscript and accompanying images.
A 70-year-old male with no comorbidities other than essential hypertension was diagnosed with liver metastases from a NET of unknown origin in 2004 and came to our institute for a second opinion. Eastern Cooperative Oncology Group performance status was 0. After a careful review of the patient's medical history, the multidisciplinary medical team recommended a wedge resection of liver segments IV and V, hepatic hilum lymphadenectomy, appendectomy, and cholecystectomy, performed in November of the same year. The histology report revealed liver and lymph node metastases from a well differentiated NET and chronic mild cholecystitis. No evidence of neoplastic disease was found in the other surgical specimens.
In 2010, a whole body CT scan and 68 Ga PET/CT showed systemic recurrence with skeletal and liver involvement. The patient also performed a 18 FDG-PET/CT which, however, did not show increased metabolic uptake. Given the indolent course of the patient's disease, the multidisciplinary team decided to start 1st-line therapy with long-acting release (LAR) octreotide at a dose of 30 mg following subcutaneous induction. After the 1st subcutaneous administration of octreotide the patient developed dyspnea and glottis edema which rapidly resolved with corticosteroid and antihistamine therapy. Following reevaluation by the multidisciplinary team, the patient was enrolled onto a phase II trial of peptide receptor radionuclide therapy (PRRT).
From August 2010 to May 2011 he completed 5 cycles of 177 Lutetium-DOTATATE-PRRT with a cumulative dose of 720 mCi, obtaining a partial response documented in both morphological and metabolic imaging studies. From August 2014 to April 2015 the patient underwent 1st-line metronomic capecitabine, showing a partial response in the liver lesions but progression in terms of the increased number and extension of bone metastases. These unusual findings were discussed by our institute's Osteoncology Multidisciplinary Group and a new radionuclide evaluation with both 68 Ga PET/CT and 18 F-FDG PET/CT was performed. The former showed widespread, intensely 68 Ga-avid skeletal disease (standardized uptake value (SUV)max at the left iliac crest: 83) and liver involvement (SUVmax: 47.6) (Fig. 1A) . The 18 F-FDG PET/CT revealed very mild to mild tracer uptake in a few pelvic and vertebral bone lesions (SUVmax at the left iliac crest: 4.1) (Fig. 1B) .
Given the discrepancy between the visceral and skeletal response to 1st-line chemotherapy and the suspicion of the presence of a concurrent prostatic tumor, a 18 F-CH PET/CT was performed. Corresponding 18 F-CH PET/CT images documented mild-to-moderate uptake in a number of axial and appendicular skeletal lesions (SUVmax at the left iliac crest: 7.5) (Fig. 1C) . Coregistered CT imaging showed a sclerotic pattern of some prominent lumbosacral and pelvic bony lesions that were positive to 68 Ga-DOTATOC. A CT-guided bone biopsy of an osteoblastic lesion at the left iliac crest positive to both 18 F-CH and 68 Ga PET/CT was carried out (Fig. 2) , the histology revealing a bone localization from a NET G1 according to the 2010 WHO classification. Immunohistochemical assays were positive for synaptophysin and negative for prostate specific antigen, chromogranin A, transcription termination factor 1, and caudal type homeobox 2. Ki67 proliferation index was 1% (Fig. 3) . The patient underwent treatment with temozolomide from July 2015 to December 2015, maintaining stable disease. However, progression was documented in January 2016 and the patient was enrolled onto a phase II PRRT retreatment trial, which is currently ongoing.
Discussion
Over the past decade, the advent of new diagnostic tools such as 68 Ga-DOTA-peptide PET/CT and the use of novel therapeutic agents have led to an increase of survival of patients with NETs. [1] [2] [3] [4] Thus, the identification of easily assessable prognostic parameters is crucial for an accurate evaluation both at baseline and during the course of the disease because an initially indolent tumor may become aggressive. To this purpose, PET/CTs provide a functional evaluation of the whole tumor burden that is not feasible with the commonly used Ki-67 parameter. [16] [17] [18] [19] CH PET/CTs
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Medicine also represent an optimal imaging modality for the assessment of bone metastases from prostate cancer, showing high specificity. [20] Beheshti et al evaluated 70 patients with biopsy-proven prostate cancer submitted to 18 F-CH PET/CT for either preoperative staging (n = 32) or follow-up evaluation (n = 38). The accuracy of bone metastasis detection was 84%. [21] Comparing 11 C-CH PET/CT with MRI in prostate cancer staging, Eschmann et al observed similar high accuracy in the detection of bone metastases for both imaging modalities. [22] Radiolabeled CH uptake reflects the increased demands of this precursor for the synthesis of membrane phospholipids in tumor cells with a high proliferation rate. [21] Based on this, radiolabeled CH was introduced as a PET tracer for brain tumors and prostate cancer in 1970. [12, 15] Numerous case reports and clinical studies have also been published on 18 F-CH PET/CT positivity in other solid tumors. [13, 22] In a recent paper by Sollini et al, [23] 7 patients with biochemical prostate cancer recurrence underwent 18 F-CH PET/CT and positive lesions were biopsied. Lung cancer was found in 5 patients, colorectal cancer in 1 patient, and lymph node metastases from melanoma in 1 patient. In a case report by Vadrucci et al, [24] a 79-year-old patient with prostate cancer showed 18 F-CH uptake in a left pelvic lymph node and the right breast, the latter histologically diagnosed as infiltrating ductal carcinoma. Piccardo et al [25] observed that a lymph node metastasis in the left laterocervical region of a patient with differentiated thyroid cancer was negative to 18 F-FDG PET/CT but correctly diagnosed by 18 F-CH PET/CT, indicating that F-CH PET/CT may provide more accurate information than 18 F-FDG PET/CT on aggressive cancers. Calabria et al [26] reported that benign tumors such as thymoma, adrenal adenoma, sarcoidosis, and meningioma can also be detected by 18 F-CH PET/CT, suggesting that these diseases should be evaluated by a nuclear physician because of the intrinsic pharmacologic property of the tracer. How Kit et al [27] reported that there were no apparent differences that could help to distinguish prostate cancer recurrence from other solid tumors in a large series of patients with increasing prostate specific antigen levels who were positive to 18F-FDG and 18F-CH PET/CT. The authors concluded that when more than 1 diagnosis is a possibility, lesions should be biopsied.
To the best of our knowledge, this is the first study to document NET-derived osteoblastic bone metastases detected by 18 F-CH PET/CT. The case described highlights some important points. First, it confirms that osteoblastic bone lesion positivity to 18 F-CH PET/CT is not only specific for metastases from prostate cancer but also for other solid neoplasms such as NETs. Furthermore, in our patient the shift from negative to positive in 18 FDG PET/CT imaging was suggestive of a transformation from indolent to more aggressive disease not detected by bone biopsy and less responsive to treatment.
CH is a precursor of phosphatidylcholine which is a membrane lipids component. The synthesis of lipid membrane and DNA takes place during cell proliferation. [28] Aberrant CH metabolism characterized by increased phosphocholine and total CHcontaining compounds reflects the complex interactions between cellular metabolism and proliferative signaling. [29] An increased CH metabolism related to a greater activity of choline kinase-a has been reported in various human malignancies, suggesting a prognostic role of choline kinase-a overexpression. [14] In our patient, 68 Ga PET/CT showed a high expression of somatostatin receptors that correlated with a more indolent clinical course, whereas 18 F-FDG PET/CT uptake indicated more aggressive disease. Of note, 18 F-CH PET/CT was more sensitive than 18 F-FDG PET/CT in several of the bone lesions, reflecting the capacity of the former scan to detect early changes in the metabolic behavior of the tumor. This could be useful for tumors in which prognostic factors are lacking.
Conclusions
18 F-CH PET/CT interpretation can be challenging because of the possibility of tracer uptake from other solid malignancies and benign lesions. NETs should also be included in the differential diagnosis of osteoblastic bone metastases showing 18 F-CH PET/ CT uptake. Our findings suggest a potential prognostic role of 18 F-CH PET/CT, which proved more sensitive than 18 F-FDG PET/CT in our patient, in NETs. Further investigation is warranted.
